Hyman Charles D acquired a new stake in shares of Biogen Inc (NASDAQ:BIIB) in the 4th quarter, HoldingsChannel reports. The fund acquired 650 shares of the biotechnology company’s stock, valued at approximately $207,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Atlantic Trust LLC bought a new position in shares of Biogen during the 2nd quarter valued at about $114,000. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Biogen by 77.0% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 174 shares during the last quarter. Horan Capital Advisors LLC. bought a new position in shares of Biogen during the 3rd quarter valued at about $128,000. Massey Quick Simon & CO. LLC boosted its holdings in shares of Biogen by 84.8% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 195 shares during the last quarter. Finally, Gs Investments Inc. bought a new position in shares of Biogen during the 2nd quarter valued at about $136,000. 88.11% of the stock is owned by institutional investors and hedge funds.
Several research firms have commented on BIIB. JPMorgan Chase & Co. reissued a “buy” rating on shares of Biogen in a report on Thursday. SunTrust Banks reaffirmed a “buy” rating and issued a $354.00 price target on shares of Biogen in a report on Tuesday, October 24th. BMO Capital Markets reaffirmed a “buy” rating on shares of Biogen in a report on Thursday, January 25th. HC Wainwright reaffirmed a “buy” rating and issued a $340.00 price target on shares of Biogen in a report on Wednesday, October 25th. Finally, Canaccord Genuity increased their price target on shares of Biogen from $340.00 to $350.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $369.03.
Shares of Biogen Inc (NASDAQ:BIIB) opened at $326.89 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 2.07. Biogen Inc has a 1 year low of $244.28 and a 1 year high of $370.57. The firm has a market cap of $70,420.76, a PE ratio of 27.42, a P/E/G ratio of 1.73 and a beta of 0.75.
Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). Biogen had a return on equity of 38.32% and a net margin of 20.69%. The firm had revenue of $3.31 billion during the quarter, compared to analysts’ expectations of $3.08 billion. During the same period last year, the company earned $5.04 earnings per share. The business’s revenue for the quarter was up 15.1% compared to the same quarter last year. equities research analysts predict that Biogen Inc will post 24.88 earnings per share for the current fiscal year.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.